$EXEL..Cabozantinib and cobimetinib to be subject of 14 presentations at 2015 @ASCO Annual Meeting: http://www.businesswire.com/news/home/20150430006940/en/Cabozantinib-Cobimetinib-Featured-Fourteen-Presentations-2015-ASCO#.VUKQeM7xP6k … #ASCO15